
а	1 50 100	150 200	250	300	350 400	450	500	550	600	650	700 753
	CRISPR target B CRISPR target C CRISPR target C CRISPR target C	>der et A		VD	J				<mark>-}</mark> CR	ISPR target D	CRISPR target E
	Leader peptide Antibody variable regio CRISPR gRNA target site PAM										
	Nucleotide sequence ATGGAATGGCCTTGTA GAGGTGACAATGACAT GCCTGGGGCCTCAGT ACTGCAGACAAATCCT ATCGTTGGTGAAGGTC ACCGTCTCCTCAGGTA GTCCCTGAGGGAGCCC	CCACAATTTCT GAAGATTTCC GGATTGGACG ITCAGCACAG CTCTACTATGA IGAATGGCCTC GGCTGAGAAA	TTCTCCC TGCAAGG GATTTAT CCTACAT/ TTACGAC CTCCAGG AATGGTA/	GACAG GTTCTGC CCTGGAG CCAACTC GGGGGGG TCTTTACT VATAAACTO	GTCCACTCC GCTACGCATA ATGGAGATA AGCAGCCTC GAACTTTTT TTTCACCTTT GTCTAGGGAT	CAGGTTO CAGTAAC CTAACTA GACATCTO GACTATAC CTTATGGO	CAGCTG CTCCTG CAATGG AGGAC CTGTGG AGTTTTC	CAGCAG GATGAA GAAGT ICTGCG ACTGCT	TCTGGA CTGGGT ICAGGG GTCTAC GGGGTC <i>TGACG</i> G	ACCTGAG GAAGCA GCAAGG TTCTGCC CAAGGAA ACTAATC	CTGGTGAA GAGGCCTG CCACACTG CCACACACTG CCACACACAC CCTCAGTC TIGGATATTT
	CTAAGAGTCTGTGTGT	/HSQVQLQQS(	GPELVKPC	GASVKISC	KASGYAFSN			GLEWIG	RIYPGDO	GDTNYNG	GKFRGKATL
b	leader CRISPR target F	150 200	250 leade	300 er	35 <u>0</u> 400	450 VJ	500	550	6Q0	650 CRISPR	700 7 CRISPR target H target I
	Leader peptide Antibody variable regio CRISPR gRNA target sit PAM										
	ATGGAGAAAGACACA CCATCATGACTTTCCA GGTTTCTCAGAGTGAT CCTGTGTGTTTCTCAT CCACCATCTCCTGCAC	TGTTTCTGGAT ATCCACAGTC TCCAG <b>GTTCC</b>	TCTTGAT ATTCTTAA ACAGGTC		CTTAGGGTAT AACTGAGAG IGCTGACCC	TTGTCATT GTCCTCT AATCTCC	IGGTTTT GCTGGG AGCTTC	AAGATT AAGGTA	CCTCAG ATGTCCA TGTGTC	TCCCCT( CATACAT	GGATTTTCT GACAATAG GCAGAGGG
	CCAAGCTCCTCATCTA CTCAACATCCATCCTG	TGGAGGAGG	ATGATAC	TGCAATG	GGGTCCCTG TATTTCTGTC	CCAGGTI	TAGTGO CTAAGG	AGGTTC	GGTCTG CATTCA	CGTTCG	ACTTCAGC GCTCGGGG
		TGGAGGAGG AAACGTAAGTA	ATGATAC	TGCAATG GCTCATT	GGGTCCCTG TATTTCTGTG TACTTGTGA	CCAGGTT CAACAAAA CGTTTTGC	TAGTGO CTAAGG	AGGTTC	GGTCTG CATTCA	CGTTCG	ACTTCAGC GCTCGGGG

MEKDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCRASESVYNYGFSFMSWFQQKPGQPPKLLIYVASNQGSGVPARFSGSG SGTDFSLNIHPVEEDDTAMYFCQQTKEVPFTFGSGTKLEIK

Supplementary Fig. 1. Annotated genomic sequence of immunoglobulin loci in WT hybridoma cells. (a) Genomic sequence of the IgH locus. (b) Genomic sequence of the IgK locus. Translated ORF were predicted from the gDNA and cDNA sequences. CRISPR gRNA target sites were independently tested (see Supplementary Fig. 2).



Supplementary Fig. 2. Validation of CRISPR-Cas9 targeting of immunoglobulin loci in WT hybridoma cells. (a) Flow cytometry dot plot shows expression of Cas9 (via 2A-GFP) in WT cells following transfection with pX458. (b, c) Surveyor results validate CRISPR-Cas9 targeting in IgH and IgK loci, respectively (agarose gels of all gRNA sites tested). The gRNAs selected for further experiments are in red text.

1	200	400	600	800		1,200 mRuby2	1,400	1,600	1,800	2,000	2,200 2,274
	HC	MOLOGY ARM FWD pri	mer	lox66	ISPR target J	CRISPR target	K-> stop lox2	272	HOMOLOGY A	RM	REV primer
Ho Ch DA Lo Re	Ruby2 gene prology Arm RISPR gRNA ta M xP sites rward sequen everse sequen vercase is exte	cing primer cing primer	ic region								


#### Nucleotide sequence

ACACATCTATAGTTTATATCTATAATTTAGTTAATCATGGTATTGGTGTAATAATCACTGATGTGTAAATATACATGTACTTTTATCCATTTTAGTGAATT TTGAAGTACATAACCTGTGGTAAAGGCAAATATTACTTGAACGTATCTTAAAGAAGGTTCTAAATATCTAAAGTTAGCCACTTTTGGAATTTACCAT GTGGAGCAGCAGCAGACTCAGGCCAAAAATTTATTGAGAACTTAGTCCCTGAAGTTACATCCACAACATCTGGCCAGGGCTCAGGGAAAGTGTT TGGGATGCTTTTCCTCAGGGAGGATTATGACCTGGACCCTAGCATCCTGCTGCATGACCCATGTGCCTTTTCAGTGCTTTCTCCCCTAGTTCT TCTCCAGCTGGACTAGGTCATTAACTAAGAAATGCACTGCTCATGAATATGCAAATTACTTGAGCCTATGGTAGTAAATACAGGCATGCCCACA GTAATGGTGTCTAAGGGCGAAGAGCTGATCAAGGAAAATATGCGTATGAAGGTGGTCATGGAAGGTTCGGTCAACGGCCACCAATTC TGCCTTTGACATTCTTGCCACGTCGTTCATGTATGGCAGCCGTACTTTTATCAAGTACCCGAAAGGCATTCCTGATTTCTTTAAACAGTC CTTTCCTGAGGGTTTTACTTGGGAAAGAGTTACGAGATACGAAGATGGTGGAGTCGTCACCGTCATGCAGGACACCAGCCTTGAGGA TGGCTGTCTCGTTTACCACGTCCAAGTCAGAGGGGTAAACTTTCCCTCCAATGGTCCCGTGATGCAGAAGAAGACCAAGGGTTGGGA **GCCTAATACAGAGATGATGATGATGCAGCAGATGGTGGTGGTGGTGGGGGGATACACTCATATGGCACTGAAAGTTGATGGTGGTGGCGCATCTG** TCTTGCTCTTTCGTAACAACTTACAGGTCAAAAAAGACCGTCGGGAACATCAAGATGCCCGGTATCCACGCGTTGATCACCGCCTGG AAAGGTTAGAGGAAAGTGACAATGAAATGTTCGTAGTACAACGCGAACACGCAGTTGCCAAGTTCGCCGGGCTTGGTGGTGGGGATG GACGAGCTGTACAAGTGAATAACTTCGTATAAAGTATCCTATACGAAGTTATTCACCGTCTCCTCAGGTAAGAATGGCCTCTCCAGGTCTT TATTTTTAACCTTTGTTATGGAGTTTTCTGAGCATTGCAGACTAATCTTGGATATTTGTCCCTGAGGGAGCCGGCTGAGAGAAGTTGGGAAATA AACTGTCTAGGGATCTCAGAGCCTTTAGGACAGATTATCTCCCACATCTTTGAAAAAACTAAGAATCTGTGTGGTGGTGGTGGTGGGAGTCCCTGG ATGATGGGATAGGGACTTTGGAGGCTCATTTGAAGAAGATGCTAAAACAATCCTATGGCTGGAGGGATAGTTGGGGCTGTAGTTGGAGATTTT CAGTTTTTAGAATAAAAGTATTAGTTGTGGAATATACTTCAGGACCACCTCTGTGACAGCATTTATACAGTATCCGATGCATAGGGACAAAGAGT GGAGTGGGGCACTTTCTTTAGATTTGTGAGGAATGTTCCGCACTAGATTGTTTAAAAACTTCATTTGTTGGAAGGAGGAGCTGTCTTAGTGATTGA GTCAAGGGAGAAAGGCATCTAGCCTCGGTCTCAAAAGGGTAGTTGCTGTCTAGAGAGGTCTGGTGGAGCCTGCAAAAGTCCAGCTTTCAA AGGAACACAGAAGTATGTGTATGGAATATTAGAAGATGTTGCTTTACTCTTAAGTTGGTTCCTAGGAAAAATAGTTAAATACTGTGACTTTAAAA TGTGAGAGGGTTTTCAAgtactcatttttttaaatgtccaaaattcttgtcaatca


#### mRuby2 coding sequence

MVSKGEELIKENMRMKVVMEGSVNGHQFKCTGEGEGNPYMGTQTMRIKVIEGGPLPFAFDILATSFMYGSRTFIKYPKGIPDFFKQSFPEG FTWERVTRYEDGGVVTVMQDTSLEDGCLVYHVQVRGVNFPSNGPVMQKKTKGWEPNTEMMYPADGGLRGYTHMALKVDGGGHLSCSF VTTYRSKKTVGNIKMPGIHAVDHRLERLEESDNEMFVVQREHAVAKFAGLGGGMDELYK


**Supplementary Fig. 3. Annotated sequence of PnP-mRuby locus.** PCR performed on genomic DNA from PnP-mRuby cells (clone 1E9.C3, see **Supplementary Table 1**) followed by Sanger sequencing (directly on PCR product or following bacterial cloning) verified matching to reference sequence from nucleotide position 489 to 2264. CRISPR gRNA target sites were independently tested (see **Supplementary Fig. 6**).



**Supplementary Fig. 4. Generation and characterization of PnP-mRuby clones.** (a) Flow cytometry dot plots following transfection WT cells with pX458 (with different gRNAs) and mRuby donor construct (linear). Data is before sorting for mRuby expression. (b) Flow cytometry dot plots after sorting for mRuby expression in different samples, before (bulk sorted population) or after the final single-cell sorting step. (c) DNA agarose gels of PCR on genomic DNA using the same primers shown in **Fig. 1d**. Clone 1E9 was selected for further experiments.




Supplementary Fig. 5. Characterization of PnP-mRuby cells with deletion of V<sub>L</sub>. (a) Left panel, flow cytometry dot plot shows IgK expression is still present in clone 1E9 (mRuby integrated in IgH locus). Middle panel shows 1E9 cells following transfection with pX458 with gRNAs targeting V<sub>L</sub>. Right panel shows single-cell isolated clone 1E9.C3 with nearly all IgK expression knocked out. (b) DNA agarose gel of PCRs from single-cell sorted populations from middle panel of (A). Primers used for PCR are the same shown in Fig. 1g.




**Supplementary Fig. 6. Validation of CRISPR-Cas9 targeting in mRuby gene.** Surveyor assays following transfection of PnP-mRuby cells (clone 1E9.C3) with pX458.2 and gRNAs targeting the mRuby gene.

а	GENOME									
	1 200 400 HOMOLOGY ARM FWD primer -	600 800 leader	1,000 1,200	1,400 IgKC	1,600 1,800 FLAG Tag Furin/2A leader	2,000 VDJ	2,200	2,400 2,600 HOMOLOGY AF	2,800 M REV prim	2,979 er
	Antibody variable region Antibody constant region E	Furin/2A peptide Iomology arms Forward sequencing primer Reverse sequencing primer (k	owercase)							
	Nucleotide sequence									
	AGTIAIATCIAATICCATTCATTTTTCC TAAATATACATGIACTTTTAICCATTTTAI TACATCATCATCATGATCACATTTTAICCATTT ATCATCATCATCATGATCAAGGAT CITTGAGCATGGTTTCCTCAGGGAA AGAGGGCAGGGAATTCATGATCCAGA AGTCCAGGATCCTCCCCCAAACTA AATGCAGCAGGTACTCCCCCAAAGA AAGGCAGCAGTTTCACCCCAAAGA AAGGCAGCAGTTTCACCCCAAAGA AAGGCAGCAGTTTCACCCCAAAGA AAGGCAGCAGTTTCAAAATCAGC CCTTGGCACCGGTGAACCACAC GCCATGAGGATTTCTCAAAATCGTGC CCAGGTCCTTCATTCAAAATCGTGC CCAGGTCTTTCAAAATCGTGGCACCACACACACACACACA	AIGAATTTGAAGTACATAA AAGCACCATCGGCTAAATCC GGATTATGACTTGGACCCT CATECCCACACTTGGAAAC ATCCAGCCAGACTGGTAGAC TGGACTATATTTC GGCCAGATCGGTGGCGG TGGACTATCCTGGGGGCG TGGGGCGAACAGCGCTCCG TGGGGGCGAACAGCGCTCG GGGGGAACCCCTGACCAGCATCA	CCTGTGGTAAAGGCAAATAT AGTGTTATATTGTCTAAAG AGCATCCTGCTGCATGACC CUACAATAGACTCCTGCTT CCTGGGGGAATTCAGCTCCTGCTT CCTGGGGGAATTCAGCAATCCAA GAGTTGCAGGCAATCCATG AGCTGGCCAAGCTGCAATCAA GGCATGGCCAGGGCAACCGTC TGTCTAAAGGTATCCTGCAAGCAG AGGCAATGCCGGGACGCTGCAATGG AGGCAATGCCGGACTGGAATTAT TAGGCAATGGCGGCATGCATGAGAG	TACTTGAACGTAT STGGAGCAACAAC ATGGGCCTTTTC TCCAACAGTCCC TCCAACAGTCCC TCCACAGTCCTAC TGCGGGCTGAT GACATACAGTCCAACCC GACTCCAACCC GACTCCAACCC TGCGCGCGTAA CCCTGAGGGAG GCTCATTGAACG GCCAAGAGAGGGAG	CTHANAGAAGGTICTAAIA GTGCTTGCCCAAAAATTA GTGCTTTCTCCCAAAAATTA GTGCTTTCTCCCTAACTCA GGAACCAACGTCACTCAAC GGGAACCAGGGTCACCAT GGGACCAGGGCACGGTCACCAT GGGACCAGGCACGGAC GGGACCAGCACACAGTGGACTG GCACCAGCGCACGCACA GGGCCCACAGCGCGCCTTG CGCCCGAGCAGCAGAAGTG GGGGCGCACTTCTTCAG	TICTAAAGTTAGCC TITGAGAACTTAGT TITGAGAACTTAGT AAATGTTAGGTAGTA AAATGTTAGGTAGTA AAATGTTAGGTAGTA AACTGTACCACCACT ATCTTCCCACCAT ATCTTCCCACCAT GAGTGTGAGACTAGC GAGCTGAGACTAGCAACTGAT GGAACTGAACT	CITTIGGAATTI CCTGAAGTTAC CTAGGTCATTAA GGTGCAGATTI TAAAATTATTITI TCACAATCAGC CCAGTGAGCAG CCAGTGAGCAG CCAGTGAGCAG CCGGCGCGCGGG CCGAAAATTTAA GGGGCACCCTG TIACGGACTCA TAGGGACTCAA	ACCATCAGAITCATCAT TCCGACACATCTGG CTAAGAAATGCACTG TCAAGCTTCCTGTTAAT SCATCTCAGTTCTTCTACT AGCATGGAGGGTGA TTTAACGACATGGAGGGC CGATAAGAGGAAAG CCGTAAGAGGAAAG CGTGAAAATTAGCTC GTGAACCGTCGGCAG GTGACCGTCGGAGA GACCTTGGAGACAG GTGGACAGACTTCAT	ATCATCATCATCA CAGGCTCAGGG CAGGCTCAGGC CAGGCTCAGGC GCATGGTACCA GCATCGTACCA GCCTCAGTCGT GCCTCAGTCGT GCCTCAGTCGT GCCTCAGTCGT GCCTCAGTCGT GGGTAAGAACGAC GGGTAAGAACGAC GGGTAAGAACGAC GGGTAAGAACGAC GGGTAAGAACGAC GGTTAGCACCACAT GTTTGCAACACACACACACACACACACACACACACACACA	ICATC IAAAG AATTA AATTA AATTA AATTA AATTA AATTA AATTA AAGTA ITATT GCAG AGCC AGAA CATGT CCAG CCTCT ITTGA AAGTA AAGTA
b	ORF (IgKV to IgG2c CH)		TCAAAAGGTAGTTGCTGTC ATGTGAGAGGGGTTTTCAAgta 500 600 IgKC	700 FLAG Tag	800 900		GAACACAGAAG	0 1,300	1,400 22c - CH1	1,534
	Leader peptide Antibody variable region Antibody constant region FLAG tag	Furin/2A peptide Forward sequencing p Beverse sequencing p lowercase is external t	primer							
	Nucleotide sequence									
	ATGGATITICAGGIGCAGATITICAN AAATGTAAGTTCCAGTTACTTGCAC ATCAGCAGCATGCAGGCTGAGGAT AGCAGTTAACATCTGGAGGGCCT GCACCTACAGCATGAGCAGCACCC CAGCCGTAGCATGAGCAGACACCCA CCGGCCCTTCCGGGCATGCATGGATT CGAAGATAGCGCGGGTGTATTATTGC CAGGGACTGGACCCTAGGATC CCGGGCCTGGACCCCAGACCT CCCCCCATGCGCAGCCTCCAGACCT CCCCCCTGGTTAGCTACACACCCT GATCAGCTGAACCAGCCCCCCCAT GGACAGCGGTTGTGGAACACACGT GAAAGAGGAAGTCTTTTCGCCTGC	TEGTACCAGCAGAAGCC/ EGTGCCACTTATTATCACGCC CAGTOGTGTGCTTATTACAGCC CAGTOGTGACCAAGGACC CACAACCAGAAATTTGTG GCCACTTCACCAGCA GCCCAGTGATAGCAGCGG GCCCGTGATAGCAGCGGT GCCCAGCCAGCCATCA CTTGGGTGACCATCCG GGAGTACACCACCGTCA CCCCCATCGAGAAAACC/	AGGATCCTCCCCCCAAACTC ACCCAGTATCATCCCCCAAAGAC ACCAGTATGACGACATAACAG GATATGAACGACATAACAG GCGCCGCGGAACTGATGACAG AGGCGCGGCGGAACTGATGA AGCGGCAGCACCCAACTAC CGCCTTGCCATGCCA	TGGATTTATAGC GCCCACGTTCG SATCAATGTCAA GTATACCTGTG TGAATTTTGACC AACCGGCGCGC AACCGAAAAATTT CAGGCAACCCCT GACCTGGAACTGT GGCAAGCAGCAGC ATCAAGGATGTA GGATTACAACAG CAGTAAGAGAC	ACATCCAACCTGGCTTC1 GTGCTGGGACCAAGCTG GTGCTGGAAGATTGATGGCAI AGGCCACTCACAAGACA TTCTCAAAGTTGACGGGA AGCGTGAAAATTAGCTG AAAGGCAAAAGTAACGACCTT GGTGACCCTCATCCACG CCCAAAGTGGACCACGAG CTCATGATCTCCCTGAG CCCACAGGTATATGTCTTG ACCGCAACAGTCCTGGA	IGAAGTCCCAGCT GAAATCAAACGG GTGAACGACAAAA CCAAGCGACCAG GACGTCGACGGG CAAAGCGACCGG GCCAAACCAACAA GTGTGCACAACCA GTGTGCACAACCA GTGTGCCCCCC GTGCCCCCCCGGCA GTGCCCCCCCGGCA CCCCCACGGCA	CGCTTCAGTGG GCTGATGCTGC/ TTGGCGTCCTGA TTGTCAAGAGC AACCCTGGGCC CTATACCTTTAG CAGCAGCAACAA CAGCAGCAACAA CCCCCCTCCC AGTGCCCCATAAQ TGCTGCTGGTGGTGGTG GAAGAGATGAC	ICAGTGGGTCTGGA ACCAACTGGACTGAT IACAAGTIGACTGAT TTCAACAGGAATGAT CAACAGGAATGAT CCACGTATATGGATG CCACGTATATGCAGC CTGCCAGTCTGGCCC CTGCCAGTCTGGCCC CTGCCAGTCGCCCCCTGT GGATGTGAGCGAGG GACTGGATGAAGTGA	CCTCTACTTACTCTC CTTCCCACCATCC CAGGACAGCAAA HTGTGACTACAAG TCTTGTGACTACAAG TGAGCAGCCTGA TGAGCAGCCTGA TGAGCAGCCTCAAAG ATGACCCAGACG AAGGAGTTCAAA ATCTGACCTGCAT	CACA AGTG GACA GATG GTTGA GCGT CCAG TACAA AGCT AGCT
С	;									
	Leader peptide Antibody variable region Antibody constant region FLAG tag									
	ORF (IgKV to IgG2c CH) translation									
	MDFQVQIFSFLLISASVIMSRGDIVLTQ S V V C F L N N F Y P K D I N V K MMVLSLLVLITALPGILSEVQLOOSCG GGTTGSSVTLGCLVKGYFPEPVTLTW NVEVHTAQTOTHREDVNSTLRVVSAL GLHNHLTTKTISRSLGK	W K I D G S E R Q N G AELMKPGASVKISCKATGY NSGSLSSGVHTFPALLQSG	V L N S W T D Q D S K D TFSNYWIGWVKQRPGHGLE GLYTLSSSVTVTSNTWPSQTI	) S T Y S M S S WIGEILPGSGST TCNVAHPASSTK	T L T L T K D E Y E R NYNEKFKGKATFTADTSS VDKKIEPRVPITQNPCPPL	H N S Y T C E A NTAYMQLSSLTSEI .KECPPCAAPDLLC	T H K T S T S F DSAVYYCARDSS GGPSVFIFPPKIK	PIVKSFNRNE GGFAYWGQGTLVTV DVLMISLSPMVTCVV	C D Y K D D D D SAAKTTAPSVYPL DVSEDDPDVQISV	K APVC VFVN

**Supplementary Fig. 7. Genomic characterization of PnP-HEL23 cells.** (a) Genomic sequence of the IgH locus in PnP-HEL23 cells with integrated sAb constructs. PCR and cloning was performed on genomic DNA, which was followed by Sanger sequencing, which verified consensus agreement to reference sequence from nucleotide positions 489 to 2912. (b) Sequence of the unique transcript coding the full-length antibody, from the leader of V<sub>L</sub> to the first exon of the IgH, CH<sub>1</sub>. RT-PCR performed on mRNA followed by Sanger sequencing verified correct splicing and matching to reference sequence from nucleotide positions 21 to 1288. (c) Predicted amino acid sequence of the translated ORF. The two dashes (-) in red indicate the ribosomal skipping and furin cleavage site (Furin/2A). The PnP-HEL23 sequence throughout the figure corresponds to the consensus between clones Y and AC (see **Supplementary Table 1**).



Supplementary Fig. 8. Evaluation of gRNA and HDR donor formats for generation of PnP-HEL23 cells. Different gRNAs and HDR donor formats were evaluated for the generation PnP-HEL23 cell lines. Flow cytometry dot plots correspond to the pre-IgH sorting phase, analogous to Fig. 2d, which displays the format with highest efficiency (gRNA-J, linear HDR donor). (a) gRNA-J, plasmid HDR donor. (b) gRNA-K, plasmid HDR donor. (c) gRNA-K, linear HDR donor.



Supplementary Fig. 9. Uncropped DNA agarose gel pictures. (a) Genomic  $V_H$  locus from WT hybridoma and engineered PnP-mRuby cell line (ref.: Fig. 1d). (b) Genomic  $V_L$  locus from WT hybridoma and engineered PnP-mRuby cell line (ref.: Fig. 1g). (c) Genomic  $V_H$  locus from WT hybridoma, PnP-mRuby and PnP-HEL23 reprogrammed cell lines (ref.: Fig. 2g). (d) Spliced HEL23 synthetic antibody (sAb) amplified by RT-PCR (ref.: Fig. 2h). (e) Spliced HyHEL10, 2G4, 4G7 and HEL23.2 sAbs amplified by RT-PCR (ref.: Fig. 4f).

## Table S1. Summary of hybridoma clones used and generated in this study.

Cell Name	Cell line clone	Description
WT	WEN1.3	WEN1.3 cells are derived from a mouse infected with LCMV. They express IgG2c and are specific for LCMV GP-1 antigen. Their IgH and IgK loci were sequenced and annotated (as shown in Fig. S1)
PnP-mRuby	1E9.C3	WEN1.3 cells were transfected with pX458 with gRNA-E and mRuby donor construct and sorted for Cas9 positive expression (2A-GFP). This was followed by a first round of sorting for mRuby-positive cells, followed by a second single-cell sort for mRuby. A single-cell clone was selected and then transfected with pX458 with gRNA-F and H and sorted for Cas9 positive expression (2A-GFP). Cells were single-cell sorted for IgK negative expression, followed by genomic PCR to identify a clone with V <sub>L</sub> deletion. This final clone represents 1E9.C3
PnP-HEL23	Y	Clone 1E9.C3 was transfected with pX458.2 with gRNA-J and HEL23 sAb donor (linearized). Cells were sorted for Cas9 positive expression (2A-BFP) and expanded. Cells were then sorted for surface IgH expression and expanded, and finally characterized for IgH and IgK expression.
PnP-HyHEL10	U	Clone 1E9.C3 was transfected with pX458.2 with gRNA-J and HyHEL10 sAb donor (linearized). Cells were sorted for Cas9 positive expression (2A-BFP) and expanded. Cells were then sorted for surface IgH expression and expanded, and then they underwent a second IgH sort. They were finally characterized for IgH and IgK expression.
PnP-2G4	AA	Clone 1E9.C3 was transfected with pX458.2 with gRNA-J and 2G4 sAb donor (linearized). Cells were sorted for Cas9 positive expression (2A-BFP) and expanded. Cells were then sorted for surface IgH expression and expanded, and then they underwent a third sort for IgH and IgK expression. They were finally characterized for IgH and IgK expression.
PnP-4G7	AB	Clone 1E9.C3 was transfected with pX458.2 with gRNA-J and 4G7 sAb donor (linearized). Cells were sorted for Cas9 positive expression (2A-BFP) and expanded. Cells were then sorted for surface IgH expression and expanded, and then they underwent a third sort for IgH and IgK expression. They were finally characterized for IgH and IgK expression.
PnP-HEL23.2	AC	Clone 1E9.C3 was transfected with pX458.2 with gRNA-J and HEL23 sAb donor (linearized). Cells were <b>not</b> sorted for Cas9 positive expression. They were sorted only once for surface IgH expression and expanded. They were finally characterized for IgH and IgK expression.

### Table S2. List of all gRNAs used in this study.

gRNA ID	Target region	gRNA (oligonucleotide)	Resident plasmid
gRNA-A	WEN1.3 leader-VH intron	GCTGTCGGGAGAAAGAAATTG	pX458
gRNA-B	WEN1.3 leader-VH intron	GCCCTATCTCCTCTTCAGAT	pX458
gRNA-C	WEN1.3 leader-VH intron	GTTCCAATCTGAAGAGGAGAT	pX458
gRNA-D	WEN1.3 JH downstream intron	GGAGCATGACGGACTAATCT	pX458
gRNA-E	WEN1.3 JH downstream intron	GTTGGTTTTAGCGGAGTCCC	pX458
gRNA-F	WEN1.3 VK leader	GGAGAAGCAGGACCCATAGC	pX458
gRNA-G	WEN1.3 VK leader	GGCTATGGGTCCTGCTTCTC	pX458
gRNA-H	WEN1.3 JK downstream intron	GGGATCTTCTATTGATGCAC	pX458
gRNA-I	WEN1.3 JK downstream intron	GTGGCTAAATGAGCCATTCC	pX458
gRNA-J	mRuby2	GTCATGGAAGGTTCGGTCAA	pX458.2 (BFP)
gRNA-K	mRuby2	GCATGCCGTTGATCACCGCC	pX458.2 (BFP)

### Table S3. Flow cytometry labeling reagents with their working concentrations.

Target antigen	Working concentration	Dilution from stock	Incubation volume	Fluorophore	Product ID
lgG2C	3.3 μg/ml	1:150	100 µl	Allophycocyanin (APC)	115-135-208 (Jackson ImmunoResearch)
lgK	2.5 μg/ml	1:80	100 µl	Brilliant Violet 421 <sup>™</sup>	409511 (BioLegend)
Hen egg lysozyme	0.99 µg/ml	1:62.5	100 µl	AlexaFluor <sup>®*</sup> 647	62971-10G-F (Sigma- Aldrich)

Lysozyme from hen egg white was labeled in-house with the AlexaFluor<sup>®\*</sup> 647 Protein labeling kit (Molecular Probes<sup>TM</sup>, Thermo Fisher Scientific, A-20173). A stock solution concentrated 61.8  $\mu$ g/ml was used for dilution.

# Table S4. Genotyping primers.

Primer name	Amplified region	Sequence
lgH-promoter-for	IgH locus (gDNA)	5'-GATGCTTTTCCTCAGGGAGGATTATG-3'
lgH-ext-rev	IgH locus (gDNA)	5'-TGATTGACAAGAATTTTGGACATTTAAAAAAATGAG-3'
IgK-upstream-for	IgK locus (gDNA)	5'-AGAGACAGGAGGATCTGGTCTATAAAATGA-3'
lgKJ5-rev	IgK locus (gDNA)	5'-CACCGAACGTGAGCCACAGTG-3'
HEL23-VK-leader- for	Spliced HEL23 antibody construct (cDNA)	5'-GGTGCAGATTTTCAGCTTC-3'
HyHEL10-VK- leader-for	Spliced HyHEL10 antibody construct (cDNA)	5'-TTTCACACCTCAGATACTTGG-3'
2G4-VK-leader-for	Spliced 2G4 antibody construct (cDNA)	5'-GTGTGCCCACTCAGGTC-3'
4G7-VK-leader-for	Spliced 4G7 antibody construct (cDNA)	5'-CCTGGGGTTGCTGCTG-3'
lgG2C-rev	Spliced antibody constructs (cDNA)	5'-GTTGTACCTCCACACAG-3'

Primers utilized for PCR on genomic DNA and RNA/cDNA.